Sector
PharmaceuticalsOpen
₹18.86Prev. Close
₹18.86Turnover(Lac.)
₹0.06Day's High
₹18.86Day's Low
₹17.9252 Week's High
₹29.2152 Week's Low
₹4.68Book Value
₹0.98Face Value
₹10Mkt Cap (₹ Cr.)
10.84P/E
0EPS
0Divi. Yield
024 Aug 2023
12:00 AM
AGM
Announcement Date: 24 Aug, 2023
14 May 2024
12:00 AM
Board Meeting
Agenda : Audited Result
| Y/e 31 Mar( In .Cr) | Mar-2023 | Mar-2022 | Mar-2021 | Mar-2020 |
|---|---|---|---|---|
Equity Capital | 6.53 | 6.53 | 6.53 | 6.53 |
Preference Capital | 0 | 0 | 0 | 0 |
Reserves | -5.43 | -5.3 | -5.14 | -5.14 |
Net Worth | 1.1 | 1.23 | 1.39 | 1.39 |
Minority Interest |
| Y/e 31 Mar( In .Cr) | Mar-2021 | Mar-2020 | Mar-2017 | Mar-2016 |
|---|---|---|---|---|
Revenue | 0 | 0 | 0 | 0 |
yoy growth (%) | 0 | 0 | 0 | 0 |
Raw materials | 0 | 0 | 0 | 0 |
As % of sales | 0 | 0 | 0 | 0 |
Employee costs | -0.05 | -0.09 | -0.07 | -0.03 |
| Y/e 31 Mar( In .Cr) | Mar-2021 | Mar-2020 | Mar-2017 | Mar-2016 |
|---|---|---|---|---|
Profit before tax | -0.23 | -0.31 | 0 | -0.06 |
Depreciation | 0 | 0 | 0 | 0 |
Tax paid | 0 | 0 | 0 | 0 |
Working capital | 0.09 | -2.52 | -0.16 | 0.01 |
Other operating items |
| Y/e 31 Mar | Mar-2021 | Mar-2020 | Mar-2017 | Mar-2016 |
|---|---|---|---|---|
Growth matrix (%) | ||||
Revenue growth | 0 | 0 | 0 | 0 |
Op profit growth | -31.43 | 166.89 | 31.01 | 18.5 |
EBIT growth | -24.06 | 15,191.52 | -96.91 | 110.74 |
Net profit growth | -24.1 | 15,171.95 | -96.92 | 110.79 |
Company Name | LTP (₹) | P/E (%) | Mkt.Cap (₹Cr.) | NP Qtr (₹Cr.) | Div.Yield (%) | Sales Qtr (₹.Cr) | Book Value (₹) |
|---|---|---|---|---|---|---|---|
Sun Pharmaceuticals Industries Ltd SUNPHARMA | 1,568.45 | 123.31 | 3,76,323.69 | 867.6 | 0.86 | 5,536.99 | 98.75 |
Divis Laboratories Ltd DIVISLAB | 4,520.1 | 76.17 | 1,19,994.45 | 531 | 0.66 | 2,259 | 507.93 |
Cipla Ltd CIPLA | 1,485.15 | 32.29 | 1,19,928.54 | 1,038.4 | 0.57 | 3,444.92 | 346.41 |
Zydus Lifesciences Ltd ZYDUSLIFE | 1,144.6 | 33.51 | 1,15,173.54 | 1,405.2 | 0.26 | 3,172.6 | 156.19 |
Dr Reddys Laboratories Ltd DRREDDY | 6,639.05 | 25.85 | 1,10,759.07 | 1,034.8 | 0.6 | 5,081.8 | 1,458.96 |
Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.
Director
Prakash Shah
Director
Ganpat Dhondu Salekar
Independent Director
Shirish Shetye
Independent Director
Parul Dave
Director
Suman Shah
Company Sec. & Compli. Officer
Bhavana Tak
Tel: -
Website: -
Email: -
Tel: -
Website: -
Email: -
Reports by Bacil Pharma Ltd
Summary
Incorporated as a private limited company in Maharashtra in May 87, Bacil Pharma (BPL) was converted into a public limited company in Oct.90. The main business activity of the Company is Pharmaceutical.Bal Pharma is a fully integrated and leading Indian pharmaceutical company specialized in Prescription drugs, Branded Formulations, APIs, Generic & OTC products, Intravenous Infusions and Bulk Drugs. Domestic operations are spread across pan India. The company has strong field force of 500 plus, spread over various States and Districts. It has a strong distribution set up, with Super Stockist in all the States and stockists for retail coverage. To augment the domestic market, Companys operations are based on focused approach.Multi-Speciality division Vibrant specialises in various specialties, like Anti-Infectives, Pain Management, Respiratory Care, Womens Health, to name a few. Aziwin, Ebay, Balvibe, MNF, Ocium and Monogesic Plus Gel (Innovative Pain Relieving Gel, first time in India) are some of the leading brands in the respective segments. Bal Vedics Division integrates modern medicine with herbal/ayurvedic preparation targeting specific conditions like, Prostrate Enlargement, Renal Calculi, Male Infertility, Women Health etc. Bal Pharma Institutional division is associated with the top Government bodies and Hospitals to extend its product range to the masses. Every area is well covered and supplied through there channel partners.Bal Pharma Unit - 1, is a finished dosage f
Read More
What is the Bacil Pharma Ltd share price today?
The Bacil Pharma Ltd shares price on BOMBAY STOCK EXCHANGE (BSE) is Rs.₹18.4 today.
What is the Market Cap of Bacil Pharma Ltd?
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Bacil Pharma Ltd is ₹10.84 Cr. as of 22 Jul ‘24
What is the PE and PB ratio of Bacil Pharma Ltd?
The PE and PB ratios of Bacil Pharma Ltd is 0 and 19.15 as of 22 Jul ‘24
What is the 52 Week High and Low of Bacil Pharma Ltd?
The 52-week high/low is the highest and lowest price at which a Bacil Pharma Ltd stock has traded during that given time period (similar to 1 year) and is considered as a technical indicator. The 52 week high and low of Bacil Pharma Ltd is ₹4.68 and ₹29.21 as of 22 Jul ‘24
What is the CAGR of Bacil Pharma Ltd?
Bacil Pharma Ltd's CAGR for 5 Years at 52.59%, 3 Years at 41.55%, 1 Year at 107.71%, 6 Month at 151.80%, 3 Month at 0.05% and 1 Month at -21.45%.
What is the shareholding pattern of Bacil Pharma Ltd?
The shareholding pattern of Bacil Pharma Ltd is as follows:
Promoters - 42.67 %
Institutions - 0.00 %
Public - 57.33 %
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Securities Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2024, IIFL Securities Ltd. All Rights Reserved
www.indiainfoline.com is part of the IIFL Group, a leading financial services player and a diversified NBFC. The site provides comprehensive and real time information on Indian corporates, sectors, financial markets and economy. On the site we feature industry and political leaders, entrepreneurs, and trend setters. The research, personal finance and market tutorial sections are widely followed by students, academia, corporates and investors among others.
Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
